Enliven Therapeutics (ELVN) Accumulated Expenses (2019 - 2026)

Enliven Therapeutics (ELVN) has 8 years of Accumulated Expenses data on file, last reported at $2.3 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 81.76% year-over-year to $2.3 million; the trailing twelve-month figure through Mar 2026 stood at $2.3 million (down 81.76% YoY), and the FY2025 full-year result was $4.3 million, down 70.53% from the prior year.
• Accumulated Expenses declined to $2.3 million in Q1 2026, from $4.3 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $15.4 million in Q4 2023 to a low of $1.1 million in Q3 2022.
• A 5-year average of $6.8 million and a median of $4.8 million in 2022 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses surged 586.39% in 2025 and tumbled 81.76% in 2026, its largest moves.
• Tracing ELVN's Accumulated Expenses over 5 years: stood at $6.3 million in 2022, then surged by 144.73% to $15.4 million in 2023, then declined by 5.14% to $14.6 million in 2024, then tumbled by 70.53% to $4.3 million in 2025, then sank by 47.31% to $2.3 million in 2026.
• Business Quant data shows ELVN's Accumulated Expenses at $2.3 million in Q1 2026, $4.3 million in Q4 2025, and $13.2 million in Q3 2025.